[go: up one dir, main page]

ATE382061T1 - Mittel zur induktion von apoptosis und zur therapieanwendung - Google Patents

Mittel zur induktion von apoptosis und zur therapieanwendung

Info

Publication number
ATE382061T1
ATE382061T1 AT95929976T AT95929976T ATE382061T1 AT E382061 T1 ATE382061 T1 AT E382061T1 AT 95929976 T AT95929976 T AT 95929976T AT 95929976 T AT95929976 T AT 95929976T AT E382061 T1 ATE382061 T1 AT E382061T1
Authority
AT
Austria
Prior art keywords
pct
apoptosis
agents
induction
sec
Prior art date
Application number
AT95929976T
Other languages
English (en)
Inventor
Barbara Ann Spruce
Alan Prescott
Angelika Boettger
Deborah Ann Dewar
Original Assignee
Univ Dundee
Barbara Ann Spruce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417444A external-priority patent/GB9417444D0/en
Priority claimed from GB9419285A external-priority patent/GB9419285D0/en
Application filed by Univ Dundee, Barbara Ann Spruce filed Critical Univ Dundee
Application granted granted Critical
Publication of ATE382061T1 publication Critical patent/ATE382061T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Optical Head (AREA)
  • Laser Beam Printer (AREA)
  • Liquid Crystal (AREA)
  • Mechanical Light Control Or Optical Switches (AREA)
  • Electronic Switches (AREA)
  • Magnetic Treatment Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT95929976T 1994-08-30 1995-08-30 Mittel zur induktion von apoptosis und zur therapieanwendung ATE382061T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417444A GB9417444D0 (en) 1994-08-30 1994-08-30 Agents for inducing apoptosis and applications of said agents in therapy
GB9419285A GB9419285D0 (en) 1994-09-23 1994-09-23 Agents for inducing apoptosis and applications of said agents in therapy

Publications (1)

Publication Number Publication Date
ATE382061T1 true ATE382061T1 (de) 2008-01-15

Family

ID=26305534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929976T ATE382061T1 (de) 1994-08-30 1995-08-30 Mittel zur induktion von apoptosis und zur therapieanwendung

Country Status (7)

Country Link
US (1) US5968824A (de)
EP (1) EP0778848B1 (de)
JP (1) JPH10508575A (de)
AT (1) ATE382061T1 (de)
AU (1) AU3352495A (de)
DE (1) DE69535673D1 (de)
WO (1) WO1996006863A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6344475B1 (en) * 1998-10-27 2002-02-05 Yale University Conductance of improperly folded proteins through the secretory pathway
EP1094063A1 (de) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazole als Bax-Modulatoren
EP1125925A1 (de) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amin-Derivate zur Behandlung von Apoptosis
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
AU2001251508A1 (en) * 2000-04-11 2001-10-23 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US20050031610A1 (en) * 2002-07-19 2005-02-10 Tae-Wan Kim CD44-related fragments, compositions and methods
US7875270B2 (en) * 2002-09-17 2011-01-25 Abbott Medical Optics Inc. Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
US7985405B2 (en) * 2002-09-17 2011-07-26 Jin Jun Zhang Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
AU2004222653C1 (en) * 2003-03-17 2010-10-07 Amo Groningen B.V. New method
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP2006265102A (ja) * 2003-05-08 2006-10-05 Taisho Pharmaceut Co Ltd ＴＧＦβ由来アポトーシス調節方法
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
JP5597793B2 (ja) 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
CN102827826B (zh) * 2012-09-11 2017-07-04 赵永祥 一种诱导树突状细胞与肿瘤细胞融合的方法
WO2017011653A1 (en) * 2015-07-15 2017-01-19 The University Of Florida Research Foundation, Inc. Tissue decellularization methods
CN118791578B (zh) * 2024-07-29 2024-12-27 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 猪繁殖与呼吸综合征病毒nsp12蛋白的抗原表位、单克隆抗体及应用

Also Published As

Publication number Publication date
DE69535673D1 (de) 2008-02-07
EP0778848A1 (de) 1997-06-18
JPH10508575A (ja) 1998-08-25
WO1996006863A1 (en) 1996-03-07
US5968824A (en) 1999-10-19
EP0778848B1 (de) 2007-12-26
AU3352495A (en) 1996-03-22

Similar Documents

Publication Publication Date Title
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE139447T1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
FI955154A0 (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE419875T1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
EP0609280A4 (en) Human il-3 variants.
DE59409735D1 (de) ALKOXYALKYLCARBAMATE VON IMIDAZO[1,2-a]PYRIDINEN
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
AU6819898A (en) Oxygen anion radicals and/or therapeutic preparations containing their reaction or breakdown products, and use of such preparations in the treatment of parkinson's disease
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties